Kiora Pharmaceuticals
KPRX
18 hedge funds and large institutions have $3.87M invested in Kiora Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
13% more funds holding
Funds holding: 16 → 18 (+2)
0.86% more ownership
Funds ownership: 41.98% → 42.85% (+0.86%)
7% less capital invested
Capital invested by funds: $4.16M → $3.87M (-$295K)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$92.2K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$17.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.4K |
| 5 |
Morgan Stanley
New York
|
+$2.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$19.3K |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$6.95K |
| 3 |
BlackRock
New York
|
-$5.38K |
| 4 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$1.72K |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.12K |
KPRX Hedge Fund Activity: Q1 2025 in Review
18 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q1 2025, worth a combined $3.87M — down 7.1% from $4.16M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new KPRX positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $92.2K. The largest seller was ADAR1 Capital Management, cutting an estimated $19.3K.
- 18 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q1 2025, up from 16 in Q4 2024.
- Funds reported $3.87M of Kiora Pharmaceuticals stock for Q1 2025, down 7.1% quarter-over-quarter.
- 3 funds opened new Kiora Pharmaceuticals positions in Q1 2025 and 1 closed out, a net change of +2 holders.
- The largest Kiora Pharmaceuticals buyer in Q1 2025 was Citadel Advisors, an estimated $92.2K added.
- The largest Kiora Pharmaceuticals seller in Q1 2025 was ADAR1 Capital Management, an estimated $19.3K sold.
Based on aggregated 13F filings for Q1 2025.